Grasselly C, Denis M, Bourguignon A, Talhi N, Mathé D, Tourette A, et al. The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. Front Immunol. 2018;9:2100 pubmed publisher

Triplett T, Garrison K, Marshall N, Donkor M, Blazeck J, Lamb C, et al. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nat Biotechnol. 2018;36:758-764 pubmed publisher

Moynihan K, Opel C, Szeto G, Tzeng A, Zhu E, Engreitz J, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med. 2016;22:1402-1410 pubmed publisher

Zelenay S, van der Veen A, Böttcher J, Snelgrove K, Rogers N, Acton S, et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell. 2015;162:1257-70 pubmed publisher

Ngiow S, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, et al. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res. 2015;75:3800-11 pubmed publisher

Zander R, Obeng Adjei N, Guthmiller J, Kulu D, Li J, Ongoiba A, et al. PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity. Cell Host Microbe. 2015;17:628-41 pubmed publisher

Vanpouille Box C, Diamond J, Pilones K, Zavadil J, Babb J, Formenti S, et al. TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Res. 2015;75:2232-42 pubmed publisher

Twyman Saint Victor C, Rech A, Maity A, Rengan R, Pauken K, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373-7 pubmed publisher

Evans E, Jonason A, Bussler H, Torno S, Veeraraghavan J, Reilly C, et al. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Cancer Immunol Res. 2015;3:689-701 pubmed publisher

Mittal D, Young A, Stannard K, Yong M, Teng M, Allard B, et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 2014;74:3652-8 pubmed publisher

McGray A, Hallett R, Bernard D, Swift S, Zhu Z, Teoderascu F, et al. Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor. Mol Ther. 2014;22:206-18 pubmed publisher

John L, Devaud C, Duong C, Yong C, Beavis P, Haynes N, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19:5636-46 pubmed publisher

Holmgaard R, Zamarin D, Munn D, Wolchok J, Allison J. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210:1389-402 pubmed publisher

Van Der Werf N, Redpath S, Azuma M, Yagita H, Taylor M. Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection. PLoS Pathog. 2013;9:e1003215 pubmed publisher

Curran M, Montalvo W, Yagita H, Allison J. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107:4275-80 pubmed publisher